This paid-for advertorial from Eurofins appeared in DDW Volume 26 – Issue 4, Fall 2025   Antibody-drug conjugates (ADCs) are increasingly promising due to advances in biologics and chemistry. With 16 FDA-approved ADCs, clinical interest is growing, though development remains complex, requiring thorough evaluation of the antibody, linker, payload, and final product.  ADCs: Preclinical and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!